The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
Inova Fairfax Hospital
3300 Gallows Road
Fairfax, VA 22031
- Confirmed cervical cancer.
- Must have adequate organ function.
- Subject is pregnant.
- Recurrent cervical cancer.
- Distant metastases.
- Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy is permissable.
- Subject has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer.
- Subject has a immunodeficiency.
- Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.
- Hypersensitivity to pembrolizumab or similar drugs.
- Subject has an active autoimmune disease in the past 2 years.
- Known history of non-infectious pneumonitis.
- Subject has an active infection.
- Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases are permissible. Talk to Study Contact for specifics.
Additional information can be found at https://clinicaltrials.gov/ct2/show/study/NCT02635360